Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Impax Labs Inc (IPXL)

Impax Labs Inc (IPXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Impax Labs Inc 30831 HUNTWOOD AVENUE HAYWARD CA 94544 USA

www.impaxlabs.com P: 510-476-2000

Description:

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the company's global pharmaceuticals division.

Key Statistics

Overview:

Market Capitalization, $K 1,351,821
Shares Outstanding, K 73,870
Annual Sales, $ 775,790 K
Annual Net Income, $ -469,290 K
Last Quarter Sales, $ 182,910 K
Last Quarter Net Income, $ -301,070 K
60-Month Beta 1.15
% of Insider Shareholders 3.20%
% of Institutional Shareholders 90.41%

Growth:

1-Year Return 38.64%
3-Year Return -59.43%
5-Year Return 5.17%
5-Year Revenue Growth 33.37%
5-Year Earnings Growth -67.02%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.11 on 03/01/18
Latest Earnings Date 05/09/18
Earnings Per Share ttm 0.63
EPS Growth vs. Prev Qtr -52.17%
EPS Growth vs. Prev Year -31.25%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

IPXL Ratios

Ratio
Price/Earnings ttm 29.05
Price/Earnings forward 15.44
Price/Earnings to Growth 0.83
Return-on-Equity % 10.42%
Return-on-Assets % 2.83%
Profit Margin % -60.49%
Debt/Equity 4.11
Price/Sales 1.74
Price/Cash Flow 8.77
Price/Book 7.25
Book Value/Share 2.53
Interest Coverage -7.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar